Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant (AMR) infections …

The rise of antibiotic resistance and a dwindling antimicrobial pipeline have been
recognized as emerging threats to public health. The ESKAPE pathogens—Enterococcus …

Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAb) is 1 of the
most problematic antimicrobial-resistant bacteria. We sought to elucidate the international …

Acinetobacter baumannii-calcoaceticus complex (ABC) causes severe infections that are
difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) …

Abstract Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that
has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by …

Aims Antimicrobial resistance is a global threat to human health, and Acinetobacter
baumannii is a paradigmatic example of how rapidly bacteria become resistant to clinically …

Objectives To perform a systematic review with meta-analysis for assessing the clinical
efficacy of cefiderocol-based regimens for the treatment of carbapenem-resistant …

In 2023, the US Food and Drug Administration has approved 55 novel medications,
consisting of 17 biologics license applications and 38 new molecular entities. Although the …

Infections caused by Acinetobacter baumannii are increasingly multidrug resistant and
associated with high rates of morbidity and mortality. Sulbactam is a β-lactamase inhibitor …

Background: The US antibiotic market failure has threatened future innovation and supply.
Understanding when and why clinicians underutilize recently approved gram-negative …